Navigation Links
Accera, Inc. Announces Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting

pound's disease modifying potential. Taken in addition to an existing AD treatment, AC-1202 was well tolerated, making it a promising co-therapeutic candidate for the chronic treatment of the disease.

Dr. Lauren Costantini is presenting the abstract, "Clinical Efficacy of AC-1202 in Mild to Moderate Alzheimer's Disease" at the Late Breaking Science session today at 3:45 p.m. EDT. The plenary session will be held at 5:15 p.m. EDT on Friday, May 4.

The trial was conducted at 25 centers across the United States, and all subjects were given the opportunity to participate in a six-month open-label extension upon completion of the three-month blinded study. The results of the open-label extension will be presented at the Alzheimer's Association's International Prevention Conference in early June.

About AC-1202

Brain imaging techniques performed on AD patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. AC-1202 is an orally available, liquid compound that is efficiently converted by the liver into ketone bodies, an alternative energy source that the brain can metabolize even when it cannot process glucose. Thus preserving the glucose- deprived brain cells, AC-1202 has disease modifying potential in AD and a number other neurodegenerative diseases characterized by neuronal metabolism. The potentially neuroprotective mechanism of this first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and canine cognitive dysfunction.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biopharmaceutical company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, AC-1202, is a first- in-class molecule currently in Phase II clinical trials for Alzheimer's disease and age-associated memory impairment. A key element of Accera's strategy is to develop AC-1202 and other small molecule com
'"/>




Page: 1 2 3

Related medicine technology :

1. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
2. Accera, Inc. to Present Results of Phase II Study in Alzheimers Disease at American Academy of Neurology Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:5/1/2015)... REDWOOD CITY, Calif. , May 1, 2015  AcelRx ... company focused on the development and commercialization of innovative ... today announced that Timothy E. Morris , chief ... events.  Details of the events are as follows: ... Tuesday, May 5 Location:  The Omni Berkshire Place, ...
(Date:4/30/2015)... MOUNTAIN VIEW, Calif., April 30, 2015 Omnicell, Inc. ... and supply management solutions to healthcare systems, today announced ... GAAP results: Revenue for the first quarter ... 14.2% from the first quarter of 2014, and down ... 2014. First quarter 2015 net income as ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics Inc ... the discovery and development of innovative medicines targeting microRNAs, ... highlights for the quarter ended March 31, 2015 on ... close. Regulus will host a conference ... 5:00 pm Eastern Daylight Time to discuss its first ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3
... maker of gloEMR, gloPM and gloSuite – the only ... practice management (PM) software with Microsoft Office built right ... This money-back guarantee ensures that doctors will be back ... of their implementation completion date or gloStream will provide ...
... 2011 Reportlinker.com announces that a new market ... The 2011 Japanese Cancer Diagnostics Market ... This report presents a comprehensive analysis of the ... issues pertaining to the Japanese laboratory practice, as ...
Cached Medicine Technology:gloStream Success Guarantee Ensures Doctors Will Be Back to Full Patient Load in as Little as 15 Days After EMR Implementation Completion 2gloStream Success Guarantee Ensures Doctors Will Be Back to Full Patient Load in as Little as 15 Days After EMR Implementation Completion 3Reportlinker Adds The 2011 Japanese Cancer Diagnostics Market 2
(Date:5/3/2015)... Leading international program provider, Child ... awarding the 2015 Harris Wofford Global Service Fellowships. CFHI ... the deserving recipients of the award named after former ... Wofford. The two recipients were chosen for their strong ... , CFHI is one of seven organizations participating ...
(Date:5/3/2015)... San Mateo, CA (PRWEB) May 03, 2015 ... newest service, MnemeTherapy® at two upcoming area seminars. The ... during the PSA Annual Regional Stroke Conference to be ... will be offered on Wednesday, May 13 during the ... Crowne Plaza. , “These seminars offer an excellent ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... We are pleased to announce the ... as one of the Top Workplaces of 2015. , ... treatment field for their ethics and standards of excellence. ... continue their educational efforts. The Delray Recovery Center prides ... their purpose – to help individuals heal from the ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2
... women's infant mortality rates in Florida is widening, Florida ... on Wednesday, the Tallahassee Democrat reports. ... Health Service division, the state's racial gap in infant ... are twice as likely to have premature babies in ...
... Japanese firm announced this week that it has developed ... significantly improve// the efficacy of chemotherapy drugs and reduce ... (NDT), the US subsidiary of Nitto Denko Corporation, says ... and biocompatible polymer material which can be loaded with ...
... The African Malaria Network Trust (AMANET) has received a ... & Melinda Gates// Foundation. ,According to the ... the four-year grant is aimed at strengthening institutional capacity ... ,It also aims at fostering and promoting discussion, ...
... drug Avastin has been tested for the first time against ... ,Duke University researchers used Avastin, known chemically as bevacizumab, ... recurrent brain tumors called gliomas. Good news -- the two ... any other therapy. ,Gliomas are mostly incurable in ...
... confirmed the presence of bird flu in their county. This ... ministry. ,The lethal H5N1 virus was found in ... was suspected, later it was diagnosed as the case of ... necessary precautions are being followed. ,Culling of birds ...
... stated a tobacco industry memo from 1969. For half a ... smoking and cancer. Now, with that effort long since failed, ... again attempting to manufacture doubt. ,"The tobacco industry ... saying that everyone knew but no one had proof," said ...
Cached Medicine News:Health News:New Cost-cutting Cancer Drug Delivery System 2Health News:New Cost-cutting Cancer Drug Delivery System 3Health News:Tobacco Companies Obstructed Science 2Health News:Tobacco Companies Obstructed Science 3
With graduation marks at 10, 50, and 100 L and MicroPoint design, it is easy to ensure accurate sample handling on single and multichannel pipettors....
This tip's tight fit and MicroPoint design make it ideal for use with the Pipetman P-20. 10 L reference mark ensures consistent pipetting with low volumes....
... Tips are available as both regular and ... by gamma-rays for more efficient sterilization and ... specifying the date of irradiation. Sterilized Diamond ... to autoclave. SterilPack Diamond Tips are wrapped ...
This ultra micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume....
Medicine Products: